AN2 Therapeutics (AN2 Therapeutics) EBIT per Share : $-3.02 (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is AN2 Therapeutics EBIT per Share?

AN2 Therapeutics's EBIT per Share for the three months ended in Dec. 2023 was $-0.63. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.02.

During the past 3 years, the average EBIT per Share Growth Rate was -78.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for AN2 Therapeutics's EBIT per Share or its related term are showing as below:

ANTX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -78.5 Med: -78.5 Max: -78.5
Current: -78.5

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of AN2 Therapeutics was -78.50% per year. The lowest was -78.50% per year. And the median was -78.50% per year.

ANTX's 3-Year EBIT Growth Rate is ranked worse than
94.8% of 1308 companies
in the Biotechnology industry
Industry Median: 3.5 vs ANTX: -78.50

AN2 Therapeutics's EBIT for the three months ended in Dec. 2023 was $-18.82 Mil.

AN2 Therapeutics EBIT per Share Historical Data

The historical data trend for AN2 Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AN2 Therapeutics EBIT per Share Chart

AN2 Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.52

-1.19

-2.76

-2.95

AN2 Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial								-0.64	-0.83	-0.85	-0.71	-0.63

AN2 Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

AN2 Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-69.635	/	23.600
=	-2.95

AN2 Therapeutics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-18.815	/	29.803
=	-0.63

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.02

AN2 Therapeutics (NAS:ANTX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

AN2 Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of AN2 Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

AN2 Therapeutics (AN2 Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AN2 Therapeutics Inc (NAS:ANTX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1800 El Camino Real, Suite D, Menlo Park, CA, USA, 94027

Website

https://www.an2therapeutics.com

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Executives

Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
Kabeer Aziz	director	376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211
Adjuvant Global Health Technology Fund De, L.p.	10 percent owner	C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Robin Shane Readnour	director	3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215
Kevin Michael Krause	officer: Chief Strategy Officer	369 27TH STREET, SAN FRANCISCO CA 94131
Eric Easom	director, officer: Chief Executive Officer	171 FOREST LN., MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Joshua M Eizen	officer: See Remarks	3023 MONTBRETIA WAY, SAN RAMON CA 94582
Margaret M Fitzpatrick	director	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Ra Capital Nexus Fund Ii, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Melvin K Spigelman	director	THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Sanjay Chanda	officer: Chief Development Officer	C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Adjuvant Global Health Technology Fund, L.p.	10 percent owner	C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Michael Adrian Nazak	officer: Chief Accounting Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
Lucy Day	officer: Chief Financial Officer	2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301